NO992309D0 - FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler - Google Patents

FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler

Info

Publication number
NO992309D0
NO992309D0 NO992309A NO992309A NO992309D0 NO 992309 D0 NO992309 D0 NO 992309D0 NO 992309 A NO992309 A NO 992309A NO 992309 A NO992309 A NO 992309A NO 992309 D0 NO992309 D0 NO 992309D0
Authority
NO
Norway
Prior art keywords
cyclooxygenase
inhibitors
angiogenic agents
angiogenic
agents
Prior art date
Application number
NO992309A
Other languages
English (en)
Norwegian (no)
Other versions
NO992309L (no
Inventor
Jaime L Masferrer
Amiram Raz
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO992309D0 publication Critical patent/NO992309D0/no
Publication of NO992309L publication Critical patent/NO992309L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO992309A 1996-11-19 1999-05-12 FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler NO992309L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19
PCT/US1997/021489 WO1998022101A2 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents

Publications (2)

Publication Number Publication Date
NO992309D0 true NO992309D0 (no) 1999-05-12
NO992309L NO992309L (no) 1999-05-12

Family

ID=21859277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992309A NO992309L (no) 1996-11-19 1999-05-12 FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler

Country Status (19)

Country Link
EP (1) EP0941080A2 (ro)
JP (1) JP2001505564A (ro)
KR (1) KR20000053362A (ro)
CN (1) CN1247470A (ro)
AU (1) AU730211B2 (ro)
BR (1) BR9713522A (ro)
CA (1) CA2270469C (ro)
CZ (1) CZ176899A3 (ro)
ID (1) ID21979A (ro)
IL (1) IL129604A (ro)
NO (1) NO992309L (ro)
NZ (1) NZ335853A (ro)
PL (2) PL194717B1 (ro)
RO (1) RO118566B1 (ro)
RU (1) RU2268716C2 (ro)
SK (1) SK59999A3 (ro)
TR (1) TR199901703T2 (ro)
UA (1) UA70294C2 (ro)
WO (1) WO1998022101A2 (ro)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
PL349216A1 (en) * 1998-12-23 2002-07-01 Searle & Co Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
EP1158977B1 (en) * 1999-03-10 2005-10-12 G.D. Searle LLC Composition for administering a cyclooxygenase-2 inhibitor to animals
RU2268054C2 (ru) * 1999-07-29 2006-01-20 Амджен Инк. Сочетанная терапия с использованием пентафторбензолсульфонамидов
EP1282418B1 (en) 2000-05-19 2005-08-17 Applied Research Systems ARS Holding N.V. Use of pyrazole derivatives for treating infertility
WO2002039958A2 (en) 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (ko) * 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
AU2003281170A1 (en) * 2002-07-17 2004-02-02 Warner-Lambert Company Llc Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
AT504159A1 (de) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
RU2475257C1 (ru) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Средство для повышения адаптируемости организма к экстремальным условиям
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE160345T1 (de) * 1993-01-15 1997-12-15 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
RO118291B1 (ro) * 1993-11-30 2003-04-30 Searle & Co Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
AU702591B2 (en) * 1994-12-21 1999-02-25 Merck Frosst Canada Ltd. Diaryl-2-(5H)-furanones as cox-2 inhibitors
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Also Published As

Publication number Publication date
PL194717B1 (pl) 2007-06-29
IL129604A0 (en) 2000-02-29
RO118566B1 (ro) 2003-07-30
WO1998022101A3 (en) 1998-06-25
CA2270469A1 (en) 1998-05-28
RU2268716C2 (ru) 2006-01-27
PL191793B1 (pl) 2006-07-31
AU730211B2 (en) 2001-03-01
CZ176899A3 (cs) 1999-10-13
WO1998022101A2 (en) 1998-05-28
BR9713522A (pt) 2000-03-21
SK59999A3 (en) 2000-01-18
ID21979A (id) 1999-08-19
CA2270469C (en) 2007-04-10
NO992309L (no) 1999-05-12
JP2001505564A (ja) 2001-04-24
TR199901703T2 (xx) 2000-07-21
KR20000053362A (ko) 2000-08-25
AU7298298A (en) 1998-06-10
NZ335853A (en) 2002-02-01
UA70294C2 (en) 2004-10-15
EP0941080A2 (en) 1999-09-15
CN1247470A (zh) 2000-03-15
IL129604A (en) 2004-08-31
PL333370A1 (en) 1999-12-06

Similar Documents

Publication Publication Date Title
DK0818448T3 (da) Cycloalkanopyridiner som CETP-inhibitorer
NO995077L (no) Fremgangsmåte ved anvendelse av cyklooksygenase-2 inhibitorer
DK1049695T3 (da) 2-Phenyl-substituerede imidazotriazinoner som phosphodiesterase-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO954427D0 (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
FI962800A0 (fi) Fenyyliheterosyklisiä yhdisteitä COX-2 inhibiittoreina
NO992309D0 (no) FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler
NO992725L (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
ID23983A (id) Inhibitor-inhibitor aminotiazol untuk kinase-kinase tergantung siklin
DK0912518T3 (da) Substituerede pyridiner som selektive cyclooxygenase-2 inhibitorer
NO20021042L (no) Benzofenoner som inhibitorer av reverstranskriptaser
FI944804A0 (fi) Pyrimidinyyliasetamideja elastaasin estäjinä
FI963597A0 (fi) Isoprenyylitransferaasi-inhibiittoreita
FI971104A (fi) Menetelmä COX-inhibiittoreina käyttökelpoisten fenyyliheterosyklien valmistamiseksi
NO940305D0 (no) Kinazolin-derivater som acetylcholin-esteraseinhibitorer
DK0593294T3 (da) Aminderivater som korrosionsinhibitorer
NO20001979D0 (no) Anvendelse av inhibitorer av renin-angiotensin-systemet
DK0912537T3 (da) Fremgangsmåde til fremstilling af phenylheterocykliske forbindelser, der er anvendelige som cox-2-inhibitorer
NO20010331D0 (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
NO922167D0 (no) Aminodukter som korrosjonshemmere
DE69523961D1 (de) Beta-Carbolin Thromboxansynthase Inhibitoren
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
EE200000568A (et) HIV-proteaasi inhibiitorite valmistamismeetod
NO983227L (no) Blandinger som vesentlig bestÕr av polyetylen, samt fremgangsmÕte for Õ fre
PT1069885E (pt) Solucao oftalmica que compreende glicogenio

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application